Therapy News and Research

RSS

Viagra ingredient improves symptoms in patients with Leigh syndrome

Sildenafil – an active ingredient also marketed under the name of Viagra – improves symptoms in patients with Leigh syndrome.

11 Mar 2026

New consensus defines oligometastatic stage in pancreatic cancer

Until now, the following has been true for metastatic pancreatic cancer: Once the tumor has spread, local treatment such as surgery is usually no longer an option.

10 Mar 2026

Study links p-tau217 levels to long-term dementia risk in women

Researchers from the University of California San Diego have found that a novel blood-based biomarker can predict a woman's risk of developing dementia as many as 25 years before symptoms appear.

10 Mar 2026

Targeting IGF2BP2 improves anti-angiogenic therapy effectiveness in colorectal cancer

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC).

10 Mar 2026

New biotech partnership aims to accelerate stem cell therapies for heart disease

A new biotech company forged through an Australian and Danish partnership will accelerate treatments for children and adults with heart disease. Harnessing cellular therapies, the company aims to conduct human clinical trials within three to five years.

10 Mar 2026

FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.

10 Mar 2026

Postbiotics may help treat PCOS by restoring microbiome balance

Emerging studies suggest postbiotics could aid PCOS management by restoring gut microbiome balance and enhancing insulin sensitivity and hormonal regulation.

10 Mar 2026

4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer.

From 4basebio PLC 10 Mar 2026

New strategy to fight chronic kidney inflammation

Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells – also known as "zombie cells" – in diabetic kidney disease.

10 Mar 2026

Using engineered bacteria to breach tumor defenses

Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S. VanNieuwenhze, Ph.D., FRSC, University Distinguished Professor and chair of the Department of Biology, along with Baylor doctoral students and a colleague at Texas Tech University Health Sciences Center, published their promising research in Cell Chemical Biology.

10 Mar 2026

Microbial ecosystems influence success of cancer checkpoint immunotherapy

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

9 Mar 2026

Boron neutron capture therapy shows promise for deadly brain tumors

Malignant gliomas are among the deadliest brain cancers, with limited treatment options and poor survival.

9 Mar 2026

Protein aggregates in the liver may protect against alcohol-induced damage

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

9 Mar 2026

New CRISPR technique boosts mitochondrial function to treat heart failure

After a heart attack, the heart struggles to recoup and maintain energy. One third of patients develop heart failure as a result ⎯ a condition that impacts 6.8 million Americans and carries a high lifetime risk with 1 in 4 adults in the U.S. expected to develop the condition during their lifetime.

9 Mar 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

Women face higher liver fibrosis risk from cardiometabolic factors than men

Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors.

9 Mar 2026

Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients' bleeding or clotting risks, despite previous lab results that raised alarms.

9 Mar 2026